London, United Kingdom – Plexus Ventures is pleased to announce it served as advisor to Celon Pharma SA and Polfarmex SA in the out-licensing of Salmex® Orbicel® (fluticasone/salmeterol), a generic version of GSK’s Advair® Diskus®, to an undisclosed company for France.

Michael O’Sullivan, Managing Partner (London), the Plexus Ventures partner responsible for the project, commented: “We are extremely pleased we were able to help our client succeed in this project. This was a complex transaction requiring significant time and energy from all parties involved. We have shown once again that our persistence leads to success even in the most challenging assignments.”